PDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on Tuesday

Key Points

• PDS Biotechnology (PDSB) is set to announce its Q2 2025 earnings results on August 12th, with analysts expecting a loss of ($0.24) per share.
• The company's stock recently traded at $1.14 and has experienced a market capitalization of $52.02 million along with a negative price-to-earnings ratio of -1.20.
• HC Wainwright has maintained a "buy" rating on PDS Biotechnology with a price target of $13.00, while Wall Street Zen downgraded the stock from a "hold" to a "sell" rating.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect PDS Biotechnology to post earnings of ($0.24) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Price Performance

Shares of PDSB stock opened at $1.11 on Thursday. PDS Biotechnology has a 12 month low of $0.85 and a 12 month high of $4.29. The company has a market capitalization of $50.74 million, a PE ratio of -1.18 and a beta of 0.95. The firm's 50-day moving average is $1.37 and its two-hundred day moving average is $1.34. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.33 and a quick ratio of 2.33.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PDSB shares. HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of PDS Biotechnology in a report on Tuesday, July 1st. Wall Street Zen lowered PDS Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, June 14th.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.